Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to compare the efficacy and safety of intralesional PPD versus intralesional Vitamin D for cutaneous warts.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Efficacy and Safety of Intralesional Purified Protein Derivative Versus Vitamin D for the Treatment of Cutaneous Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Source: Article title.

Efficacy and Safety of Intralesional Purified Protein Derivative Versus Vitamin D for the Treatment of Cutaneous Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Efficacy and Safety of Intralesional Purified Protein Derivative Versus Vitamin D for the Treatment of Cutaneous Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Systematic review · Journal of Clinical Medicine · 2026

Original publication title

Efficacy and Safety of Intralesional Purified Protein Derivative Versus Vitamin D for the Treatment of Cutaneous Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ahmed Abu-Zaid; Samira Hilali; Zainab Albasheer; Shouq Alkhatlan; Fanr F. Alraqum; Abdulmuhsin H. Al-Rashid; Malak A. Alshamali; Faisal Fahad AlSuwailem; Abdullah N. Almutairi; Waleed Alfailakawi; Abdullah M. Alharran

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Cutaneous warts, caused by HPV, are common, and conventional destructive treatments often fail to prevent recurrence. Intralesional immunotherapy offers a promising alternative. Specifically, purified protein derivative (PPD) and vitamin D have demonstrated efficacy; however, a direct comparison of their therapeutic value and safety profiles is needed. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to compare the efficacy and safety of intralesional PPD versus intralesional Vitamin D for cutaneous warts.

Methods:

A comprehensive search of PubMed, Scopus, CENTRAL, and Google Scholar was conducted for RCTs up to November 2025. Primary outcomes were the complete and partial clinical response rates of warts. Secondary outcomes included recurrence and adverse events. Risk ratios (RRs) with 95% confidence intervals (CIs) and p-values were pooled using STATA 19.5.

Results:

Seven RCTs involving 520 patients were included. The analysis found no significant difference in the rate of complete clinical response (RR: 1.07, 95% CI [0.95, 1.21]; p = 0.24) or partial clinical response (RR: 0.90, 95% CI [0.56, 1.46]; p = 0.68) between the two groups. Also, the two groups showed no significant difference in recurrence rate (RR: 1.14, 95% CI [0.48, 2.68]; p = 0.77). Regarding safety, PPD was associated with a significantly higher risk of injection site erythema (RR: 4.76, 95% CI [2.08, 10.93]; p < 0.001) and flu-like symptoms/fever (RR: 8.28, 95% CI [1.59, 43.18]; p = 0.01). Still, no significant differences were found for injection site pain (p = 0.12) or swelling (p = 0.68).

Conclusions:

With uncertain evidence, intralesional PPD and vitamin D demonstrate comparable overall efficacy in clearing cutaneous warts. However, PPD carries a higher risk of systemic adverse events (fever) and injection site erythema, with a more effective potential to clear distant warts. The choice between the two agents should be based on the clinical profile and patient preference.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Cutaneous warts, caused by HPV, are common, and conventional destructive treatments often fail to prevent recurrence. Intralesional immunotherapy offers a promising alternative. Specifically, purified protein derivative (PPD) and vitamin D have demonstrated efficacy; however, a direct comparison of their therapeutic value and safety profiles is needed. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to compare the efficacy and safety of intralesional PPD versus intralesional Vitamin D for cutaneous warts.

Source: Background

Abstract: Results

Seven RCTs involving 520 patients were included. The analysis found no significant difference in the rate of complete clinical response (RR: 1.07, 95% CI [0.95, 1.21]; p = 0.24) or partial clinical response (RR: 0.90, 95% CI [0.56, 1.46]; p = 0.68) between the two groups. Also, the two groups showed no significant difference in recurrence rate (RR: 1.14, 95% CI [0.48, 2.68]; p = 0.77). Regarding safety, PPD was associated with a significantly higher risk of injection site erythema (RR: 4.76, 95% CI [2.08, 10.93]; p < 0.001) and flu-like symptoms/fever (RR: 8.28, 95% CI [1.59, 43.18]; p = 0.01). Still, no significant differences were found for injection site pain (p = 0.12) or swelling (p = 0.68).

Source: Results

Abstract: Conclusions

With uncertain evidence, intralesional PPD and vitamin D demonstrate comparable overall efficacy in clearing cutaneous warts. However, PPD carries a higher risk of systemic adverse events (fever) and injection site erythema, with a more effective potential to clear distant warts. The choice between the two agents should be based on the clinical profile and patient preference.

Source: Conclusions
Authors’ abstract

Background:

Cutaneous warts, caused by HPV, are common, and conventional destructive treatments often fail to prevent recurrence. Intralesional immunotherapy offers a promising alternative. Specifically, purified protein derivative (PPD) and vitamin D have demonstrated efficacy; however, a direct comparison of their therapeutic value and safety profiles is needed. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to compare the efficacy and safety of intralesional PPD versus intralesional Vitamin D for cutaneous warts.

Methods:

A comprehensive search of PubMed, Scopus, CENTRAL, and Google Scholar was conducted for RCTs up to November 2025. Primary outcomes were the complete and partial clinical response rates of warts. Secondary outcomes included recurrence and adverse events. Risk ratios (RRs) with 95% confidence intervals (CIs) and p-values were pooled using STATA 19.5.

Results:

Seven RCTs involving 520 patients were included. The analysis found no significant difference in the rate of complete clinical response (RR: 1.07, 95% CI [0.95, 1.21]; p = 0.24) or partial clinical response (RR: 0.90, 95% CI [0.56, 1.46]; p = 0.68) between the two groups. Also, the two groups showed no significant difference in recurrence rate (RR: 1.14, 95% CI [0.48, 2.68]; p = 0.77). Regarding safety, PPD was associated with a significantly higher risk of injection site erythema (RR: 4.76, 95% CI [2.08, 10.93]; p < 0.001) and flu-like symptoms/fever (RR: 8.28, 95% CI [1.59, 43.18]; p = 0.01). Still, no significant differences were found for injection site pain (p = 0.12) or swelling (p = 0.68).

Conclusions:

With uncertain evidence, intralesional PPD and vitamin D demonstrate comparable overall efficacy in clearing cutaneous warts. However, PPD carries a higher risk of systemic adverse events (fever) and injection site erythema, with a more effective potential to clear distant warts. The choice between the two agents should be based on the clinical profile and patient preference.

Publication and source details

Original title: Efficacy and Safety of Intralesional Purified Protein Derivative Versus Vitamin D for the Treatment of Cutaneous Warts: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ahmed Abu-Zaid; Samira Hilali; Zainab Albasheer; Shouq Alkhatlan; Fanr F. Alraqum; Abdulmuhsin H. Al-Rashid; Malak A. Alshamali; Faisal Fahad AlSuwailem; Abdullah N. Almutairi; Waleed Alfailakawi; Abdullah M. Alharran

Journal of Clinical Medicine · 2026

* Correspondence: amabuzaid@alfaisal.edu© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T10:37:47.011283+00:00

DOI: 10.3390/jcm15103564 · PMC13206856